secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000394
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight reports preliminary Q4 2022 revenue $16.1M, up 91% YoY; full-year $49.0M, up 117%
--------------------------------------------------------------------------------

- Q4 2022 revenue $16.1M (+91% YoY); 57 LDDs sold, installed base 400 LDDs as of Dec 31, 2022.
- Full-year 2022 revenue $49.0M (+117% YoY); 25,284 LALs sold.
- Preliminary cash, equivalents & short-term investments $105.8M, including $6.0M ATM net proceeds.
- Management expects continued growth in 2023; audited results targeted for early March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017023000394/0000950170-23-000394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017023000394/rxst-20230108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer